Alx Oncology Holdings (ALXO) Accumulated Expenses (2019 - 2026)

Alx Oncology Holdings' Accumulated Expenses history runs 8 years deep, the most recent figure standing at $1.8 million for Q1 2026.

• In Q1 2026, Accumulated Expenses fell 52.06% year-over-year to $1.8 million; the TTM figure through Mar 2026 stood at $1.8 million (down 52.06% YoY), while the FY2025 annual figure was $4.4 million, down 17.9% from the prior year.
• Accumulated Expenses came in at $1.8 million for Q1 2026 at Alx Oncology Holdings, down from $4.4 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $30.1 million in Q2 2024 to a low of $1.8 million in Q1 2026.
• A 5-year average of $9.8 million and a median of $4.6 million in 2024 frame the typical range for Accumulated Expenses.
• Across the five-year window, Accumulated Expenses surged 898.24% in 2024 and sank 85.32% in 2025, its largest moves.
• Alx Oncology Holdings' Accumulated Expenses stood at $3.7 million in 2022, then soared by 624.57% to $26.9 million in 2023, then sank by 80.25% to $5.3 million in 2024, then decreased by 17.9% to $4.4 million in 2025, then sank by 58.59% to $1.8 million in 2026.
• According to Business Quant data, Accumulated Expenses over the past three periods registered $1.8 million, $4.4 million, and $2.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison